AVIR

3.50

0.28% -0.010

Handel nachbörslich: 3.43 -0.07 -2.00%

Atea Pharmaceuticals Inc (AVIR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$3.51

Offen:

$3.52

24-Stunden-Volumen:

371.58K

Relative Volume:

0.94

Marktkapitalisierung:

$277.75M

Einnahmen:

$351.37M

Nettoeinkommen (Verlust:

$-174.01M

KGV:

-1.6908

EPS:

-2.07

Netto-Cashflow:

$-126.94M

1W Leistung:

+0.29%

1M Leistung:

-4.63%

6M Leistung:

+12.54%

1J Leistung:

-4.37%

1-Tages-Spanne:

$3.475

$3.60

1-Wochen-Bereich:

$3.33

$3.64

52-Wochen-Spanne:

$2.455

$4.145

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Firmenname

Atea Pharmaceuticals Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (646)

Telefon

857-204-8109

Adresse

225 FRANKLIN STREET, BOSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

AVIR's Discussions on Twitter

Vergleichen Sie AVIR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AVIR Atea Pharmaceuticals Inc	3.50	278.55M	351.37M	-174.01M	-126.94M	-2.07
VRTX Vertex Pharmaceuticals Inc	395.92	96.01B	11.42B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	561.55	57.86B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	432.52	57.02B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	646.60	39.10B	3.05B	1.28B	-614.78M	19.58
ONC Beone Medicines Ltd Adr	307.51	34.45B	3.81B	-644.79M	-669.77M	-6.24

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-13	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2023-08-10	Herabstufung	JP Morgan	Neutral → Underweight
2022-01-06	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2021-11-18	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-10-20	Herabstufung	JP Morgan	Overweight → Neutral
2021-10-05	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-11-25	Eingeleitet	Evercore ISI	Outperform
2020-11-24	Eingeleitet	JP Morgan	Overweight
2020-11-24	Eingeleitet	Morgan Stanley	Overweight
2020-11-24	Eingeleitet	William Blair	Outperform

Alle ansehen

Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten

12:06 PM

Atea Pharmaceuticals’ Earnings Call Highlights HCV Progress - MSN

12:06 PM

09:25 AM

What Fibonacci levels say about Atea Pharmaceuticals Inc. reboundAnalyst Upgrade & Weekly High Conviction Ideas - Newser

09:25 AM

09:23 AM

Volatility clustering patterns for Atea Pharmaceuticals Inc.2025 Year in Review & Reliable Entry Point Trade Alerts - Newser

09:23 AM

09:22 AM

What earnings revisions data tells us about Atea Pharmaceuticals Inc.Share Buyback & Step-by-Step Trade Execution Guides - Newser

09:22 AM

08:15 AM

Published on: 2025-08-13 07:15:38 - Newser

08:15 AM

07:04 AM

Analyzing net buyer seller activity in Atea Pharmaceuticals Inc.July 2025 Price Swings & High Accuracy Trade Signal Alerts - Newser

07:04 AM

04:24 AM

Atea Pharmaceuticals Inc. stock momentum explainedEarnings Summary Report & Weekly Stock Performance Updates - Newser

04:24 AM

Aug 12, 2025

Regression analysis insights on Atea Pharmaceuticals Inc. performance [Earnings Risk Summary]Free Short-Term High Return Strategies - Newser

Aug 12, 2025

Detecting support and resistance levels for Atea Pharmaceuticals Inc. [Profit Target]Stock Market Timing Techniques - Newser

Aug 12, 2025

Why Atea Pharmaceuticals Inc. stock attracts strong analyst attentionFree Alpha Driven Watchlist With Alerts - Newser

Aug 12, 2025

Quantitative breakdown of Atea Pharmaceuticals Inc. recent moveFree Investment Strategy With Predictable Gains - Newser

Aug 12, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 12, 2025

How institutional ownership impacts Atea Pharmaceuticals Inc. stockMulti-Year Signal Summary and Entry Timing - Newser

Aug 12, 2025

Will Atea Pharmaceuticals Inc. price bounce be sustainableDaily Market Momentum and Pressure Analysis - Newser

Aug 12, 2025

What candlestick patterns are forming on Atea Pharmaceuticals Inc.Trend Following Ideas with Volume Confirmation - Newser

Aug 12, 2025

How to build a custom watchlist for Atea Pharmaceuticals Inc.Free Swing Setup With Technical Confirmation - Newser

Aug 12, 2025

Aug 11, 2025

Atea Pharmaceuticals Inc. stock outlook for YEARFree High Accuracy Alerts for ROI Traders - Newser

Aug 11, 2025

Institutional scanner results for Atea Pharmaceuticals Inc.AI-Based Reversal Point Prediction Signal - Newser

Aug 11, 2025

Does Atea Pharmaceuticals Inc. fit your quant trading modelFree Triple Return Setup with Risk Control - Newser

Aug 11, 2025

Using data tools to time your Atea Pharmaceuticals Inc. exitFree Swing Setup With Technical Confirmation - Newser

Aug 11, 2025

Atea Pharmaceuticals Inc. stock daily chart insightsEntry Timing Tracker with Alert Accuracy - Newser

Aug 11, 2025

Aug 10, 2025

Signal strength of Atea Pharmaceuticals Inc. stock in tech scannersEarnings Report Summary with Market Impact - Newser

Aug 10, 2025

Visualizing Atea Pharmaceuticals Inc. stock with heatmapsBreakout Watcher with Entry and Exit Alerts - Newser

Aug 10, 2025

Aug 09, 2025

Is Atea Pharmaceuticals Inc. forming a bottoming baseAI Trading Forecast Based on Big Data - Newser

Aug 09, 2025

Atea Pharmaceuticals (AVIR): A High-Growth HCV Play with Clinical and Financial Momentum - AInvest

Aug 09, 2025

Is Atea Pharmaceuticals Inc. meeting your algorithmic filter criteriaReal Time Alert System for Market Moves - Newser

Aug 09, 2025

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Rating Lowered by Wall Street Zen - Defense World

Aug 09, 2025

Aug 08, 2025

William Blair Keeps Their Buy Rating on Atea Pharmaceuticals (AVIR) - The Globe and Mail

Aug 08, 2025

When is the best time to exit Atea Pharmaceuticals Inc.Momentum-Based Prediction for Quick Returns - Newser

Aug 08, 2025

Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway - Investing.com Canada

Aug 08, 2025